Decidual Regeneration Approaches in Reproductive Health

Abstract

Recent advances in reproductive medicine underscore the pivotal role of the decidua in implantation, placentation, and pregnancy maintenance. Decidual regeneration has emerged as a promising frontier in addressing reproductive pathologies such as recurrent pregnancy loss, implantation failure, and abnormal placentation. This review synthesizes current knowledge on mechanisms of decidual regeneration, epidemiological relevance, pathophysiology, clinical features, diagnostic modalities, management strategies, and future directions, with a focus on recent evidence and clinical guideline recommendations. The article aims to provide clinicians and researchers with a comprehensive understanding of how innovative regenerative approaches may transform outcomes in reproductive health.

Introduction

The human endometrium is a dynamic tissue with remarkable regenerative capacity, cycling through proliferation, differentiation, and shedding during each menstrual cycle. Decidualization, the transformation of endometrial stromal cells into specialized decidual cells, is a prerequisite for embryo implantation and successful pregnancy. However, inadequate decidual regeneration or impaired decidualization has been implicated in various reproductive disorders, including recurrent implantation failure (RIF), recurrent pregnancy loss (RPL), and disorders of placentation such as preeclampsia. As regenerative medicine advances, there is growing interest in targeted therapies that enhance or restore decidual function, offering hope for individuals affected by these challenging conditions.

Epidemiology / Disease Burden

Reproductive failures related to decidual dysfunction are common, with RPL affecting approximately 1-2% of women of reproductive age and RIF encountered in up to 10% of those undergoing assisted reproductive technology (ART). Abnormal placentation complicates 2-8% of pregnancies, leading to significant maternal and perinatal morbidity and mortality. The burden of disease underscores the pressing need for novel, effective, and safe interventions that address underlying endometrial pathology and support optimal decidual regeneration.

Pathophysiology

Decidual regeneration involves the proliferation and differentiation of endometrial stromal cells, orchestrated by a complex interplay of hormonal signals (especially progesterone), cytokines, growth factors, and extracellular matrix remodeling. Aberrant signaling, impaired stem/progenitor cell function, dysregulated immune responses, and oxidative stress can compromise decidualization. Chronic endometritis, fibrosis, or iatrogenic injury (e.g., from curettage or infection) may further disrupt regenerative potential, predisposing women to implantation failure and adverse pregnancy outcomes.

Risk Factors

Risk factors for impaired decidual regeneration include advanced maternal age, uterine instrumentation, chronic endometritis, intrauterine adhesions (Asherman syndrome), endocrine disorders (e.g., polycystic ovary syndrome, thyroid dysfunction), obesity, and immune dysregulation. A history of uterine surgery or infection is particularly relevant in the context of secondary infertility, as repeated endometrial injury can diminish regenerative capability. Genetic and epigenetic factors are increasingly recognized as contributors to individual susceptibility.

Clinical Features

Clinical manifestations of defective decidual regeneration are often nonspecific but may include unexplained infertility, recurrent miscarriage, abnormal uterine bleeding, or adverse obstetric events such as preeclampsia and placental insufficiency. In ART settings, repeated implantation failure despite transfer of high-quality embryos warrants investigation for endometrial pathology. Chronic pelvic pain and menstrual irregularities may suggest underlying endometrial dysfunction or adhesions.

Diagnosis

Diagnostic evaluation is multifaceted, encompassing clinical history, transvaginal ultrasound, hysteroscopy, and endometrial biopsy. Sonographic assessment can reveal endometrial thickness, echogenicity, and vascularity, while hysteroscopy allows direct visualization and targeted sampling of suspicious lesions. Histopathological analysis may demonstrate chronic inflammation, fibrosis, or inadequate decidual transformation. Emerging molecular and immunohistochemical markers (e.g., HOXA10, IGFBP-1, prolactin, uNK cell density) provide additional insights into endometrial receptivity and regenerative status.

Treatment & Management

Current management of decidual dysfunction is largely supportive and tailored to underlying etiology. Hormonal therapies (e.g., progesterone supplementation, estrogen priming) remain central, particularly in ART protocols. Antibiotic therapy may be indicated for chronic endometritis. Surgical adhesiolysis can restore cavity anatomy in selected cases, but may risk further injury. The role of immunomodulation, antioxidant supplementation, and lifestyle modification is under investigation. Optimal timing and synchronization of embryo transfer with a receptive endometrium are critical for maximizing success.

Recent Advances / Emerging Therapies

Regenerative medicine approaches are rapidly evolving, with attention focused on endometrial stem/progenitor cell therapy, platelet-rich plasma (PRP) infusion, and growth factor delivery. Autologous bone marrow-derived stem cell transplantation has demonstrated endometrial regeneration and restored fertility in cases of severe Asherman syndrome. PRP, rich in cytokines and growth factors, is increasingly applied intrauterinely to promote endometrial proliferation and decidualization. Tissue engineering strategies, including bioengineered scaffolds and organoids, offer experimental avenues for personalized regeneration. Ongoing trials are evaluating the efficacy, safety, and long-term reproductive outcomes of these interventions.

Guideline Recommendations

International guidelines from societies such as ESHRE and ASRM emphasize thorough evaluation of uterine anatomy and endometrial function in the workup of RIF and RPL. While hormonal support and surgical correction remain first-line, the use of regenerative therapies should be restricted to research settings or specialized centers due to limited evidence and regulatory considerations. Multidisciplinary collaboration and individualized care planning are advocated, with a strong focus on patient counseling and shared decision-making.

Conclusion

Decidual regeneration represents a critical determinant of reproductive success and a promising target for therapeutic innovation. While conventional strategies provide benefit for many, emerging regenerative interventions hold transformative potential for individuals with refractory endometrial dysfunction. Continued translational research, rigorous clinical trials, and evidence-based guideline development are essential to ensure safe, effective, and equitable integration of these novel approaches into reproductive healthcare.